Gordana Halec1, Tim Waterboer2, Nicole Brenner2, Julia Butt2, W David Hardy3, Gypsyamber DʼSouza4, Steven Wolinsky5, Bernard J Macatangay6, Michael Pawlita2, Roger Detels7, Otoniel Martínez-Maza1, Shehnaz K Hussain7,8. 1. Department of Obstetrics and Gynecology, AIDS Institute, UCLA David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA. 2. Infections and Cancer Epidemiology, Research Program Infection, Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. 3. Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD. 4. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 5. Division of Infectious Diseases, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL. 6. Division of Infectious Diseases, Department of Medicine, University of Pittsburg School of Medicine, Pittsburgh, PA. 7. Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA. 8. Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
Abstract
BACKGROUND: HIV infection is associated with increased susceptibility to common pathogens, which may trigger chronic antigenic stimulation and hyperactivation of B cells, events known to precede the development of AIDS-associated non-Hodgkin lymphoma (AIDS-NHL). METHODS: To explore whether cumulative exposure to infectious agents contributes to AIDS-NHL risk, we tested sera from 199 AIDS-NHL patients (pre-NHL, average lead time 3.9 years) and 199 matched HIV-infected controls from the Multicenter AIDS Cohort Study, for anti-IgG responses to 18 pathogens using multiplex serology. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using conditional logistic regression models. RESULTS: We found no association between cumulative exposure to infectious agents and AIDS-NHL risk (OR 1.01, 95% CI: 0.91 to 1.12). However, seropositivity for trichodysplasia spinulosa polyomavirus (TSPyV), defined as presence of antibodies to TSPyV capsid protein VP1, was significantly associated with a 1.6-fold increase in AIDS-NHL risk (OR 1.62, 95% CI: 1.02 to 2.57). High Epstein-Barr virus (EBV) anti-VCA p18 antibody levels closer to the time of AIDS-NHL diagnosis (<4 years) were associated with a 2.6-fold increase in AIDS-NHL risk (OR 2.59, 95% CI: 1.17 to 5.74). In addition, high EBV anti-EBNA-1 and anti-ZEBRA antibody levels were associated with 2.1-fold (OR 0.47, 95% CI: 0.26 to 0.85) and 1.6-fold (OR 0.57, 95% CI: 0.35 to 0.93) decreased risk of AIDS-NHL, respectively. CONCLUSIONS: Our results do not support the hypothesis that cumulative exposure to infectious agents contributes to AIDS-NHL development. However, the observed associations with respect to TSPyV seropositivity and EBV antigen antibody levels offer additional insights into the pathogenesis of AIDS-NHL.
BACKGROUND: HIV infection is associated with increased susceptibility to common pathogens, which may trigger chronic antigenic stimulation and hyperactivation of B cells, events known to precede the development of AIDS-associated non-Hodgkin lymphoma (AIDS-NHL). METHODS: To explore whether cumulative exposure to infectious agents contributes to AIDS-NHL risk, we tested sera from 199 AIDS-NHL patients (pre-NHL, average lead time 3.9 years) and 199 matched HIV-infected controls from the Multicenter AIDS Cohort Study, for anti-IgG responses to 18 pathogens using multiplex serology. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using conditional logistic regression models. RESULTS: We found no association between cumulative exposure to infectious agents and AIDS-NHL risk (OR 1.01, 95% CI: 0.91 to 1.12). However, seropositivity for trichodysplasia spinulosa polyomavirus (TSPyV), defined as presence of antibodies to TSPyV capsid protein VP1, was significantly associated with a 1.6-fold increase in AIDS-NHL risk (OR 1.62, 95% CI: 1.02 to 2.57). High Epstein-Barr virus (EBV) anti-VCA p18 antibody levels closer to the time of AIDS-NHL diagnosis (<4 years) were associated with a 2.6-fold increase in AIDS-NHL risk (OR 2.59, 95% CI: 1.17 to 5.74). In addition, high EBV anti-EBNA-1 and anti-ZEBRA antibody levels were associated with 2.1-fold (OR 0.47, 95% CI: 0.26 to 0.85) and 1.6-fold (OR 0.57, 95% CI: 0.35 to 0.93) decreased risk of AIDS-NHL, respectively. CONCLUSIONS: Our results do not support the hypothesis that cumulative exposure to infectious agents contributes to AIDS-NHL development. However, the observed associations with respect to TSPyV seropositivity and EBV antigen antibody levels offer additional insights into the pathogenesis of AIDS-NHL.
Authors: Eric A Engels; Stefania Pittaluga; Denise Whitby; Charles Rabkin; Yoshiyasu Aoki; Elaine S Jaffe; James J Goedert Journal: Mod Pathol Date: 2003-05 Impact factor: 7.842
Authors: Stefan Kostense; Sigrid A Otto; Gerlinde J Knol; Erik H Manting; Nening M Nanlohy; Christine Jansen; Joep M A Lange; Marinus H J van Oers; Frank Miedema; Debbie van Baarle Journal: Eur J Immunol Date: 2002-04 Impact factor: 5.532
Authors: Joseph J Carter; Kelly G Paulson; Greg C Wipf; Danielle Miranda; Margaret M Madeleine; Lisa G Johnson; Bianca D Lemos; Sherry Lee; Ashley H Warcola; Jayasri G Iyer; Paul Nghiem; Denise A Galloway Journal: J Natl Cancer Inst Date: 2009-09-23 Impact factor: 13.506
Authors: Minkyo Song; Bryan A Bassig; Noemi Bender; James J Goedert; Cheryl A Winkler; Nicole Brenner; Tim Waterboer; Charles S Rabkin Journal: AIDS Res Hum Retroviruses Date: 2020-03-02 Impact factor: 2.205
Authors: Jacky Njiki Bikoï; Esther Del Florence Moni Ndedi; Etienne Atenguena Okobalemba; Donatien Serge Mbaga; Chris André Mbongue Mikangue; Alexandra Emmanuelle Membangbi; Elsa Makue Nguiffo; Justin Olivier Essindi; George Ikomey Mondinde; Sara Honorine Riwom Essama Journal: Pan Afr Med J Date: 2022-05-19